Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer
Lung cancer is one of the malignant tumors with the highest morbidity and mortality in the world. Immune checkpoint inhibitors (ICIs), including programmed cell death 1 (PD-1) antibody, programmed cell death ligand 1 (PD-L1) antibody, and cytotoxic T lymphocyte associated protein 4 (CTLA-4) antibody...
Saved in:
Main Authors: | Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted Therapy, Chinese Society of Clinical Oncology, Expert Committee on Non-small Cell Lung Cancer |
---|---|
Format: | article |
Language: | ZH |
Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/73efbbca7aad481c9495e49e699bda8c |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Expert consensus on diagnosis, treatment and fertility management of young breast cancer patients
by: Committee of Diagnosis, Treatment, and Fertility Management of Chinese Young Breast Cancer Patients
Published: (2021) -
Chinese Expert Consensus on Iodine125 Seed Implantation for Recurrent Cervical Cancer in 2021
by: Ping Jiang, et al.
Published: (2021) -
A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors
by: Nagasaka M, et al.
Published: (2019) -
Evaluation of 30 DNA damage response and 6 mismatch repair gene mutations as biomarkers for immunotherapy outcomes across multiple solid tumor types
by: Zhe Gong, et al.
Published: (2021) -
Targeting Tumor-Associated Macrophages in Cancer Immunotherapy
by: Amy J. Petty, et al.
Published: (2021)